BIGPRO

Biguanides for the Prevention of the Risk of Obesity study. A trial that assessed the use of metformin for primary prevention of insulin resistance syndrome in middle-aged patients with upper-body obesity, which may be linked to ischaemic heart disease and type-2 diabetes.

Results
Metformin induced significant weight loss, better fasting glucose control, lower total and LDL C, and a greater reduction of fasting plasma insulin, but had no effect on blood pressure, triglycerides and HDL-cholesterol.

Conclusion
Metformin is effective for diabetes, not for heart disease.
Logistics
Randomised, double-blind; 324 patients with upper-body obesity.